evidence for oncolytic virotherapy: where have we got to and where are we going?
Clicks: 178
ID: 177548
2015
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
30.0
/100
177 views
19 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal models in a wide range of tumour types. How do we move forward into the clinical setting and translate something which has such potential into meaningful clinical outcomes? Here, we review how the field of oncolytic virotherapy has developed thus far and what the future may hold.
| Reference Key |
turnbull2015virusesevidence
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Samantha Turnbull;Emma J. West;Karen J. Scott;Elizabeth Appleton;Alan Melcher;Christy Ralph |
| Journal | International journal of pharmaceutics |
| Year | 2015 |
| DOI |
10.3390/v7122938
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.